Your support will: Increase bench-to-bedside research: The more scientific research our immunotherapy experts can perform in our labs, the more options we can translate to patients at the bedside, bringing more breakthroughs in cancer immunotherapy faster. For cancer patients and their loved ones, time is a precious gift. Grow our investigative team: The success of our efforts will only be as good as the people chosen to lead our work. We know that recruiting and training the very brightest minds is the key to a future without cancer. Provide whole-person care for patients and families: We believe in caring for the whole person and supporting the families of those in our care. Our patient advocates, nurse navigators, survivorship team, oncology palliative care, and integrative medicine services greatly improve the quality of life for cancer patients and their families. Secure the future through endowment: Through endowment, we can allow our researchers to ask the big questions, explore new ideas, and collaborate worldwide in pursuit of new breakthroughs, all while knowing that their work will have sustained funding.
To make a donation that will support the research, programs and services of Providence Cancer Institute, please call Providence Foundations of Oregon, 503-215-5546, or go to ProvidenceFoundations.org.
OUR MISSION
How you can help Give: Make a gift to Providence in support of cancer research. Get involved: Take a tour, meet our research team in person or
attend a gathering.
As people of Providence, we reveal God’s love for all, especially the poor and vulnerable, through our compassionate service. OUR CORE VALUES
Respect, Compassion, Justice, Excellence, Stewardship
Introduce: Share information about our work with others,
host Cancer Center tours or plan gatherings for your friends.
Remember: Remember Providence in your will or estate plan to ensure the future of cancer research, treatment and care.
For more information on how you can help, contact Shari Lynn Scales at 503-215-6220 or shari.scales@providence.org.
FinishCancer.org/oregon
What if the body’s immune system could identify and destroy cancer cells?
Diane Davis found hope at Providence with Dr. Li.
Our Milestones
When Walter J. Urba, M.D., Ph.D., joined Providence Portland Medical Center as director of the cancer program 25 years ago, only a few people were asking that simple “what if” question.
1987
Earle A. Chiles Research Institute at Providence Portland Medical Center is dedicated.
That didn’t stop him or his team of pioneers. Today the cancer research team at Providence has proven the immune system can fight cancer. Immunotherapy works, and we are saving more lives today than ever before.
If we’re still treating cancer the same way next year that we are today, then we’re not doing our job. If has become when. At Providence, we are constantly innovating, improving every day, and reaching for that future without cancer. Today’s treatments are better than those of yesterday, but they are still not good enough. We need tomorrow’s treatments – treatments that will get us even closer to finishing cancer. Cancer isn’t going away. It’s sneaky, changing and finding new ways to invade. And immunotherapy doesn’t work for everyone. We want to find out why and create personalized treatments so that more people have hope – hope for more time, more moments with the people they love.
We can’t do it without you. Donors provide 70 percent of our research funding. You are the catalyst. Without you, we can’t push the limits of research. We believe that we’ve got cancer on the run. With your help, we can finish it for good.
Stefano has more moments with his daughter. Treated for testicular cancer, he is alive because of progress made in cancer research.
1993
Diane finds hope at Providence Diane Davis, a resident of Corvallis, was told in 2015 she had three months to live. When she was diagnosed with stage IV ovarian cancer, Diane tried standard cancer treatments, but none of them worked. Her doctor suggested she get her affairs in order. She didn’t listen. Diane and her husband met with an oncologist in Portland to discuss treatment options, including investigational therapies. Unfortunately, Diane had TP53 mutated gene, which made her unable to participate in many clinical trials. “I was in a lot of pain,” Diane says. “I knew I was sliding downhill quickly.” Providence Cancer Institute enrolled her into a clinical trial for a combination of immunotherapies called nivolumab and varlilumab. She was the first patient with ovarian cancer to enter the study. A year later, after one of her tumors had grown, she entered another immunotherapy trial. “It was more involved than the first, and they both worked,” says Diane. After the trials, doctors noticed a significant difference in Diane’s tumors – they were gone. The drugs worked for Diane, but they don’t work for everyone. “I think she is truly a miracle,” says Rui Li, M.D., Ph.D., oncologist with Providence. “We need more research so we can help more people like Diane.”
Providence gave me hope. They weren’t going to give up on me, and I wasn’t going to give up on me either.
Diane counts each day as a blessing. “I wouldn’t be here without the amazing doctors at Providence. Each day I thank Providence for saving my life,” Diane says. She goes to routine check-ups every few months to make sure no new tumors have developed. So far so good, she says. She does not intend to die from ovarian cancer.
Walter J. Urba, M.D., Ph.D., is recruited to start cancer at Earle A. Chiles Research Institute.
1995
Research on OX40, a protein that stimulates immune cells, begins at Providence.
1995
2009
We treat world’s first patient with immune-activating IL-2 and highly-targeted radiation therapy.
2009
The first clinical trial begins using DRibble, a lung cancer vaccine developed at Providence.
2011
1997
2012
We gave Oregon’s first experimental prostate cancer vaccine, now known as Provenge.
2006
First patient in the world receives treatment to target and stimulate OX40 after donors give $2.4M for the clinical trial.
2008
Donors generously give $74M to the “Providence Together” campaign, giving $74M to build the 200,000-square-foot Providence Cancer Center, housing all cancer services under one roof.
Thanks to donors, the new Providence Guest House opens.
2011
International trial led by Dr. Urba results in first immunotherapy drug that improves melanoma survival rates. FDA approval of ipilimumab soon follows.
2000
2015
Medimmune, a division of AstraZeneca, signs an agreement with Providence to further develop anti-OX40.
We offer the world’s first treatment for late-stage melanoma using patient-derived tumor vaccine with adoptive cellular therapy and IL-2. We are the first in Oregon to test a genetically modified breast cancer vaccine.
2015
Providence physicians Kristina Young, M.D., Ph.D., and David Page, M.D., receive Young Investigator Awards from the American Society of Clinical Oncology.
2016
Providence is chosen as a founding member of the Bristol-Myers Squibb International Immuno-Oncology Network.
Immunotherapy is named “Clinical Advance of the Year” by the American Society of Clinical Oncology.
2012
2017
First patient in Oregon receives nivolumab at Providence to treat melanoma and lung cancer, resulting in FDA approval three years later.
2013
The journal Science names cancer immunotherapy the “Breakthrough of the Year.”
Providence Cancer Center becomes Robert W. Franz Cancer Center in honor of the lifetime support and generosity of Bob Franz.
What if the body’s immune system could identify and destroy cancer cells?
Diane Davis found hope at Providence with Dr. Li.
Our Milestones
When Walter J. Urba, M.D., Ph.D., joined Providence Portland Medical Center as director of the cancer program 25 years ago, only a few people were asking that simple “what if” question.
1987
Earle A. Chiles Research Institute at Providence Portland Medical Center is dedicated.
That didn’t stop him or his team of pioneers. Today the cancer research team at Providence has proven the immune system can fight cancer. Immunotherapy works, and we are saving more lives today than ever before.
If we’re still treating cancer the same way next year that we are today, then we’re not doing our job. If has become when. At Providence, we are constantly innovating, improving every day, and reaching for that future without cancer. Today’s treatments are better than those of yesterday, but they are still not good enough. We need tomorrow’s treatments – treatments that will get us even closer to finishing cancer. Cancer isn’t going away. It’s sneaky, changing and finding new ways to invade. And immunotherapy doesn’t work for everyone. We want to find out why and create personalized treatments so that more people have hope – hope for more time, more moments with the people they love.
We can’t do it without you. Donors provide 70 percent of our research funding. You are the catalyst. Without you, we can’t push the limits of research. We believe that we’ve got cancer on the run. With your help, we can finish it for good.
Stefano has more moments with his daughter. Treated for testicular cancer, he is alive because of progress made in cancer research.
1993
Diane finds hope at Providence Diane Davis, a resident of Corvallis, was told in 2015 she had three months to live. When she was diagnosed with stage IV ovarian cancer, Diane tried standard cancer treatments, but none of them worked. Her doctor suggested she get her affairs in order. She didn’t listen. Diane and her husband met with an oncologist in Portland to discuss treatment options, including investigational therapies. Unfortunately, Diane had TP53 mutated gene, which made her unable to participate in many clinical trials. “I was in a lot of pain,” Diane says. “I knew I was sliding downhill quickly.” Providence Cancer Institute enrolled her into a clinical trial for a combination of immunotherapies called nivolumab and varlilumab. She was the first patient with ovarian cancer to enter the study. A year later, after one of her tumors had grown, she entered another immunotherapy trial. “It was more involved than the first, and they both worked,” says Diane. After the trials, doctors noticed a significant difference in Diane’s tumors – they were gone. The drugs worked for Diane, but they don’t work for everyone. “I think she is truly a miracle,” says Rui Li, M.D., Ph.D., oncologist with Providence. “We need more research so we can help more people like Diane.”
Providence gave me hope. They weren’t going to give up on me, and I wasn’t going to give up on me either.
Diane counts each day as a blessing. “I wouldn’t be here without the amazing doctors at Providence. Each day I thank Providence for saving my life,” Diane says. She goes to routine check-ups every few months to make sure no new tumors have developed. So far so good, she says. She does not intend to die from ovarian cancer.
Walter J. Urba, M.D., Ph.D., is recruited to start cancer at Earle A. Chiles Research Institute.
1995
Research on OX40, a protein that stimulates immune cells, begins at Providence.
1995
2009
We treat world’s first patient with immune-activating IL-2 and highly-targeted radiation therapy.
2009
The first clinical trial begins using DRibble, a lung cancer vaccine developed at Providence.
2011
1997
2012
We gave Oregon’s first experimental prostate cancer vaccine, now known as Provenge.
2006
First patient in the world receives treatment to target and stimulate OX40 after donors give $2.4M for the clinical trial.
2008
Donors generously give $74M to the “Providence Together” campaign, giving $74M to build the 200,000-square-foot Providence Cancer Center, housing all cancer services under one roof.
Thanks to donors, the new Providence Guest House opens.
2011
International trial led by Dr. Urba results in first immunotherapy drug that improves melanoma survival rates. FDA approval of ipilimumab soon follows.
2000
2015
Medimmune, a division of AstraZeneca, signs an agreement with Providence to further develop anti-OX40.
We offer the world’s first treatment for late-stage melanoma using patient-derived tumor vaccine with adoptive cellular therapy and IL-2. We are the first in Oregon to test a genetically modified breast cancer vaccine.
2015
Providence physicians Kristina Young, M.D., Ph.D., and David Page, M.D., receive Young Investigator Awards from the American Society of Clinical Oncology.
2016
Providence is chosen as a founding member of the Bristol-Myers Squibb International Immuno-Oncology Network.
Immunotherapy is named “Clinical Advance of the Year” by the American Society of Clinical Oncology.
2012
2017
First patient in Oregon receives nivolumab at Providence to treat melanoma and lung cancer, resulting in FDA approval three years later.
2013
The journal Science names cancer immunotherapy the “Breakthrough of the Year.”
Providence Cancer Center becomes Robert W. Franz Cancer Center in honor of the lifetime support and generosity of Bob Franz.
What if the body’s immune system could identify and destroy cancer cells?
Diane Davis found hope at Providence with Dr. Li.
Our Milestones
When Walter J. Urba, M.D., Ph.D., joined Providence Portland Medical Center as director of the cancer program 25 years ago, only a few people were asking that simple “what if” question.
1987
Earle A. Chiles Research Institute at Providence Portland Medical Center is dedicated.
That didn’t stop him or his team of pioneers. Today the cancer research team at Providence has proven the immune system can fight cancer. Immunotherapy works, and we are saving more lives today than ever before.
If we’re still treating cancer the same way next year that we are today, then we’re not doing our job. If has become when. At Providence, we are constantly innovating, improving every day, and reaching for that future without cancer. Today’s treatments are better than those of yesterday, but they are still not good enough. We need tomorrow’s treatments – treatments that will get us even closer to finishing cancer. Cancer isn’t going away. It’s sneaky, changing and finding new ways to invade. And immunotherapy doesn’t work for everyone. We want to find out why and create personalized treatments so that more people have hope – hope for more time, more moments with the people they love.
We can’t do it without you. Donors provide 70 percent of our research funding. You are the catalyst. Without you, we can’t push the limits of research. We believe that we’ve got cancer on the run. With your help, we can finish it for good.
Stefano has more moments with his daughter. Treated for testicular cancer, he is alive because of progress made in cancer research.
1993
Diane finds hope at Providence Diane Davis, a resident of Corvallis, was told in 2015 she had three months to live. When she was diagnosed with stage IV ovarian cancer, Diane tried standard cancer treatments, but none of them worked. Her doctor suggested she get her affairs in order. She didn’t listen. Diane and her husband met with an oncologist in Portland to discuss treatment options, including investigational therapies. Unfortunately, Diane had TP53 mutated gene, which made her unable to participate in many clinical trials. “I was in a lot of pain,” Diane says. “I knew I was sliding downhill quickly.” Providence Cancer Institute enrolled her into a clinical trial for a combination of immunotherapies called nivolumab and varlilumab. She was the first patient with ovarian cancer to enter the study. A year later, after one of her tumors had grown, she entered another immunotherapy trial. “It was more involved than the first, and they both worked,” says Diane. After the trials, doctors noticed a significant difference in Diane’s tumors – they were gone. The drugs worked for Diane, but they don’t work for everyone. “I think she is truly a miracle,” says Rui Li, M.D., Ph.D., oncologist with Providence. “We need more research so we can help more people like Diane.”
Providence gave me hope. They weren’t going to give up on me, and I wasn’t going to give up on me either.
Diane counts each day as a blessing. “I wouldn’t be here without the amazing doctors at Providence. Each day I thank Providence for saving my life,” Diane says. She goes to routine check-ups every few months to make sure no new tumors have developed. So far so good, she says. She does not intend to die from ovarian cancer.
Walter J. Urba, M.D., Ph.D., is recruited to start cancer at Earle A. Chiles Research Institute.
1995
Research on OX40, a protein that stimulates immune cells, begins at Providence.
1995
2009
We treat world’s first patient with immune-activating IL-2 and highly-targeted radiation therapy.
2009
The first clinical trial begins using DRibble, a lung cancer vaccine developed at Providence.
2011
1997
2012
We gave Oregon’s first experimental prostate cancer vaccine, now known as Provenge.
2006
First patient in the world receives treatment to target and stimulate OX40 after donors give $2.4M for the clinical trial.
2008
Donors generously give $74M to the “Providence Together” campaign, giving $74M to build the 200,000-square-foot Providence Cancer Center, housing all cancer services under one roof.
Thanks to donors, the new Providence Guest House opens.
2011
International trial led by Dr. Urba results in first immunotherapy drug that improves melanoma survival rates. FDA approval of ipilimumab soon follows.
2000
2015
Medimmune, a division of AstraZeneca, signs an agreement with Providence to further develop anti-OX40.
We offer the world’s first treatment for late-stage melanoma using patient-derived tumor vaccine with adoptive cellular therapy and IL-2. We are the first in Oregon to test a genetically modified breast cancer vaccine.
2015
Providence physicians Kristina Young, M.D., Ph.D., and David Page, M.D., receive Young Investigator Awards from the American Society of Clinical Oncology.
2016
Providence is chosen as a founding member of the Bristol-Myers Squibb International Immuno-Oncology Network.
Immunotherapy is named “Clinical Advance of the Year” by the American Society of Clinical Oncology.
2012
2017
First patient in Oregon receives nivolumab at Providence to treat melanoma and lung cancer, resulting in FDA approval three years later.
2013
The journal Science names cancer immunotherapy the “Breakthrough of the Year.”
Providence Cancer Center becomes Robert W. Franz Cancer Center in honor of the lifetime support and generosity of Bob Franz.
Your support will: Increase bench-to-bedside research: The more scientific research our immunotherapy experts can perform in our labs, the more options we can translate to patients at the bedside, bringing more breakthroughs in cancer immunotherapy faster. For cancer patients and their loved ones, time is a precious gift. Grow our investigative team: The success of our efforts will only be as good as the people chosen to lead our work. We know that recruiting and training the very brightest minds is the key to a future without cancer. Provide whole-person care for patients and families: We believe in caring for the whole person and supporting the families of those in our care. Our patient advocates, nurse navigators, survivorship team, oncology palliative care, and integrative medicine services greatly improve the quality of life for cancer patients and their families. Secure the future through endowment: Through endowment, we can allow our researchers to ask the big questions, explore new ideas, and collaborate worldwide in pursuit of new breakthroughs, all while knowing that their work will have sustained funding.
To make a donation that will support the research, programs and services of Providence Cancer Institute, please call Providence Foundations of Oregon, 503-215-5546, or go to ProvidenceFoundations.org.
OUR MISSION
How you can help Give: Make a gift to Providence in support of cancer research. Get involved: Take a tour, meet our research team in person or
attend a gathering.
As people of Providence, we reveal God’s love for all, especially the poor and vulnerable, through our compassionate service. OUR CORE VALUES
Respect, Compassion, Justice, Excellence, Stewardship
Introduce: Share information about our work with others,
host Cancer Center tours or plan gatherings for your friends.
Remember: Remember Providence in your will or estate plan to ensure the future of cancer research, treatment and care.
For more information on how you can help, contact Shari Lynn Scales at 503-215-6220 or shari.scales@providence.org.
FinishCancer.org/oregon
Your support will: Increase bench-to-bedside research: The more scientific research our immunotherapy experts can perform in our labs, the more options we can translate to patients at the bedside, bringing more breakthroughs in cancer immunotherapy faster. For cancer patients and their loved ones, time is a precious gift. Grow our investigative team: The success of our efforts will only be as good as the people chosen to lead our work. We know that recruiting and training the very brightest minds is the key to a future without cancer. Provide whole-person care for patients and families: We believe in caring for the whole person and supporting the families of those in our care. Our patient advocates, nurse navigators, survivorship team, oncology palliative care, and integrative medicine services greatly improve the quality of life for cancer patients and their families. Secure the future through endowment: Through endowment, we can allow our researchers to ask the big questions, explore new ideas, and collaborate worldwide in pursuit of new breakthroughs, all while knowing that their work will have sustained funding.
To make a donation that will support the research, programs and services of Providence Cancer Institute, please call Providence Foundations of Oregon, 503-215-5546, or go to ProvidenceFoundations.org.
OUR MISSION
How you can help Give: Make a gift to Providence in support of cancer research. Get involved: Take a tour, meet our research team in person or
attend a gathering.
As people of Providence, we reveal God’s love for all, especially the poor and vulnerable, through our compassionate service. OUR CORE VALUES
Respect, Compassion, Justice, Excellence, Stewardship
Introduce: Share information about our work with others,
host Cancer Center tours or plan gatherings for your friends.
Remember: Remember Providence in your will or estate plan to ensure the future of cancer research, treatment and care.
For more information on how you can help, contact Shari Lynn Scales at 503-215-6220 or shari.scales@providence.org.
FinishCancer.org/oregon